| Literature DB >> 8843206 |
R W Coombs1, S L Welles, C Hooper, P S Reichelderfer, R T D'Aquila, A J Japour, V A Johnson, D R Kuritzkes, D D Richman, S Kwok, J Todd, J B Jackson, V DeGruttola, C S Crumpacker, J Kahn.
Abstract
Human immunodeficiency virus (HIV)-1 RNA level in plasma was evaluated as a surrogate marker for disease progression in a clinical trial of advanced HIV-1 infection. Baseline HIV-1 RNA level was an independent predictor of disease progression (relative hazard [RH] for each doubling of HIV-1 RNA level, 1.26; 95% confidence interval [CI], 1.03-1.54; P = .02), after adjusting for the week 4 change in HIV-1 RNA level, baseline CD4 cell count, syncytium-inducing phenotype, clinical status at study entry, and therapy randomization. A 50% reduction in HIV-1 RNA level was associated with a 27% decrease in the adjusted risk of disease progression during the study (RH, 0.73; 95% CI, 0.52-1.02; P = .07). The partial validation of HIV-1 RNA as a predictor for clinical end points has implications for the use of HIV-1 RNA in clinical trials and practice.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8843206 DOI： 10.1093/infdis/174.4.704
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226